Protection of retinal ganglion cells by caspase substrate-binding peptide IQACRG from N-Methyl-D-aspartate receptor-mediated excitotoxicity

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 2, 2010, Pages 1198-1207

  Seki, Masaaki ^a   Soussou, Walid ^a   Manabe, Shin Ichi ^a,b   Lipton, Stuart A ^a  

^a BURNHAM INSTITUTE   (United States)

^b TENRI HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AVIDIN; BIOTIN; CASPASE 3; CASPASE 7; GELATINASE B; INTERLEUKIN 1BETA CONVERTING ENZYME; ISOLEUCYLGLUTAMINYLALANYLCYSTEINYLARGINYLGLYCINE; MYOCYTE ENHANCER FACTOR 2; MYOCYTE ENHANCER FACTOR 2C; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROPROTECTIVE AGENT; PENETRATIN; POLYPEPTIDE; UNCLASSIFIED DRUG; AMINO ACID RECEPTOR STIMULATING AGENT; CASP3 PROTEIN, RAT; IQACRG PEPTIDE; MEF2C PROTEIN, RAT; MYOGENIC FACTOR; N METHYLASPARTIC ACID; OLIGOPEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CELL LABELING; CELL TRANSPORT; CONTROLLED STUDY; DRUG EFFICACY; ELECTROPHYSIOLOGY; ENZYME ACTIVITY; ENZYME INHIBITION; EX VIVO STUDY; EXCITOTOXICITY; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MALE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; RAT; RETINA GANGLION CELL; ANIMAL; APOPTOSIS; CELL CULTURE; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; ENZYME IMMUNOASSAY; FLUORESCENT ANTIBODY TECHNIQUE; INJECTION; METABOLISM; NICK END LABELING; PATHOLOGY; RETINA DISEASE; SPRAGUE DAWLEY RAT; VITREOUS BODY; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CASPASE 7; CELL SURVIVAL; CELLS, CULTURED; ELECTROPHYSIOLOGY; EXCITATORY AMINO ACID AGONISTS; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; IMMUNOENZYME TECHNIQUES; IN SITU NICK-END LABELING; INJECTIONS; MALE; MATRIX METALLOPROTEINASE 9; MYOGENIC REGULATORY FACTORS; N-METHYLASPARTATE; NEUROPROTECTIVE AGENTS; OLIGOPEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; RETINAL DISEASES; RETINAL GANGLION CELLS; VITREOUS BODY;

EID: 77449146076     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-4102     Document Type: Article

References (65)

1. Lucas DR, Newhouse JP. The toxic effect of sodium L-glutamate on the inner layers of the retina. AMA Arch Ophthalmol. 1957;58:193-201.
2. Olney JW, Ho OL. Brain damage in infant mice following oral intake of glutamate, aspartate or cysteine. Nature. 1970;227:609-611.
3. 2+: toxicity is blocked by the N-methyl-Daspartate antagonist MK-801. Proc Natl Acad Sci USA. 1988;85:6556-6560.
4. Sucher NJ, Aizenman E, Lipton SA. N-methyl-D-aspartate antagonists prevent kainate neurotoxicity in rat retinal ganglion cells in vitro. J Neurosci. 1991;11:966-971.
5. Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron. 1988;1:623-634.
6. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med. 1994;330:613-622.
7. Ambati J, Chalam KV, Chawla DK, et al. Elevated gamma-aminobutyric acid, glutamate, and vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch Ophthalmol. 1997;115:1161-1166.
8. Lieth E, Barber AJ, Xu B, et al. Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy. Penn State Retina Research Group. Diabetes. 1998;47:815-820.
9. Yoles E, Schwartz M. Elevation of intraocular glutamate levels in rats with partial lesion of the optic nerve. Arch Ophthalmol. 1998;116:906-910.
10. Dreyer EB, Lipton SA. New perspectives on glaucoma. JAMA. 1999;281:306-308.
11. Lipton SA. Retinal ganglion cells, glaucoma and neuroprotection. Prog Brain Res. 2001;131:712-718.
12. Lipton SA. Possible role for memantine in protecting retinal ganglion cells from glaucomatous damage. Surv Ophthalmol. 2003;48(suppl 1):S38-S46.
13. Wakabayashi Y, Yagihashi T, Kezuka J, Muramatsu D, Usui M, Iwasaki T. Glutamate levels in aqueous humor of patients with retinal artery occlusion. Retina. 2006;26:432-436.
14. Quigley HA. Neuronal death in glaucoma. Prog Retin Eye Res. 1999;18:39-57.
15. Naskar R, Vorwerk CK, Dreyer EB. Saving the nerve from glaucoma: memantine to caspases. Semin Ophthalmol. 1999;14:152-158.
16. Nicholson DW, Ali A, Thornberry NA, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 1995;376:37-43.
17. Troy CM, Stefanis L, Prochiantz A, Greene LA, Shelanski ML. The contrasting roles of ICE family proteases and interleukin-1beta in apoptosis induced by trophic factor withdrawal and by copper/ zinc superoxide dismutase down-regulation. Proc Natl Acad Sci USA. 1996;93:5635-5640.
18. Tenneti L, D'Emilia DM, Troy CM, Lipton SA. Role of caspases in N-methyl-D-aspartate-induced apoptosis in cerebrocortical neurons. J Neurochem. 1998;71:946-959.
19. Derossi D, Chassaing G, Prochiantz A. Trojan peptides: the penetratin system for intracellular delivery. Trends Cell Biol. 1998;8:84-87.
20. Vecil GG, Larsen PH, Corley SM, et al. Interleukin-1 is a key regulator of matrix metalloproteinase-9 expression in human neurons in culture and following mouse brain trauma in vivo. J Neurosci Res. 2000;61:212-224.
21. Allan SM, Tyrrell PJ, Rothwell NJ. Interleukin-1 and neuronal injury. Nat Rev Immunol. 2005;5:629-640.
22. Kawasaki Y, Xu Z-Z, Wang X, et al. Distinct roles of matrix metalloproteases in the early and late-phase development of neuropathic pain. Nat Med. 2008;14:331-336.
23. Gu Z, Kaul M, Yan B, et al. S-Nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science. 2002;297:1186-1190.
24. Chintala SK, Zhang X, Austin JS, Fini ME. Deficiency in matrix metalloproteinase gelatinase B (MMP-9) protects against retinal ganglion cell death after optic nerve ligation. J Biol Chem. 2002;277:47461-47468.
25. Gu Z, Cui J, Brown S, et al. A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J Neurosci. 2005;25:6401-6408.
26. Manabe S, Gu Z, Lipton S. Activation of matrix metalloproteinase-9 via neuronal nitric oxide synthase contributes to NMDA-induced retinal ganglion cell death. Invest Ophthalmol Vis Sci. 2005;46:4747-4753.
27. Leifer D, Krainc D, Yu Y, et al. MEF2C, a MADS/MEF2-family transcription factor expressed in a laminar distribution in cerebral cortex. Proc Natl Acad Sci USA. 1993;90:1546-1550.
28. Mao Z, Bonni A, Xia F, Nadal-Vicens M, Greenberg ME. Neuronal activity-dependent cell survival mediated by transcription factor MEF2. Science. 1999;286:785-790.
29. Okamoto S, Krainc D, Sherman K, Lipton SA. Antiapoptotic role of the p38 mitogen-activated protein kinase-myocyte enhancer factor 2 transcription factor pathway during neuronal differentiation. Proc Natl Acad Sci USA. 2000;97:7561-7566.
30. Okamoto S, Li Z, Ju C, et al. Dominant-interfering forms of MEF2 generated by caspase cleavage contribute to NMDA-induced neuronal apoptosis. Proc Natl Acad Sci USA. 2002;99:3974-3979.
31. Geroski DH, Edelhauser HF. Drug delivery for posterior segment eye disease. Invest Ophthalmol Vis Sci. 2000;41:961-964.
32. Ambati J, Adamis AP. Transscleral drug delivery to the retina and choroid. Prog Retin Eye Res. 2002;21:145-151.
33. Manabe S, Lipton S. Divergent NMDA signals leading to proapoptotic and antiapoptotic pathways in the rat retina. Invest Ophthalmol Vis Sci. 2003;44:385-392.
34. Otori Y, Wei JY, Barnstable CJ. Neurotoxic effects of low doses of glutamate on purified rat retinal ganglion cells. Invest Ophthalmol Vis Sci. 1998;39:972-981.
35. Seki M, Tanaka T, Nawa H, et al. Involvement of brain-derived neurotrophic factor in early retinal neuropathy of streptozotocininduced diabetes in rats: therapeutic potential of brain-derived neurotrophic factor for dopaminergic amacrine cells. Diabetes. 2004;53:2412-2419.
36. Kermer P, Klocker N, Labes M, Bahr M. Inhibition of CPP32-like proteases rescues axotomized retinal ganglion cells from secondary cell death in vivo. J Neurosci. 1998;18:4656-4662.
37. Aihara M, Lindsey JD, Weinreb RN. Reduction of intraocular pressure in mouse eyes treated with latanoprost. Invest Ophthalmol Vis Sci. 2002;43:146-150.
38. Weinreb RN. Enhancement of scleral macromolecular permeability with prostaglandins. Trans Am Ophthalmol Soc. 2001;99:319-343.
39. Derossi D, Calvet S, Trembleau A, Brunissen A, Chassaing G, Prochiantz A. Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J Biol Chem. 1996;271:18188-18193.
40. Seki M, Nawa H, Fukuchi T, Abe H, Takei N. BDNF is upregulated by postnatal development and visual experience: quantitative and immunohistochemical analyses of BDNF in the rat retina. Invest Ophthalmol Vis Sci. 2003;44:3211-3218.
41. Li H, Radford JC, Ragusa MJ, et al. Transcription factor MEF2C influences neural stem/progenitor cell differentiation and maturation in vivo. Proc Natl Acad Sci USA. 2008;105:9397-9402.
42. Xiang M, Zhou L, Peng YW, Eddy RL, Shows TB, Nathans J. Brn-3b: a POU domain gene expressed in a subset of retinal ganglion cells. Neuron. 1993;11:689-701.
43. Yoshida K, Behrens A, Le-Niculescu H, et al. Amino-terminal phosphorylation of c-Jun regulates apoptosis in the retinal ganglion cells by optic nerve transection. Invest Ophthalmol Vis Sci. 2002;43:1631-1635.
44. Kikuchi M, Tenneti L, Lipton SA. Role of p38 mitogen-activated protein kinase in axotomy-induced apoptosis of rat retinal ganglion cells. J Neurosci. 2000;20:5037-5044.
45. Danias J, Shen F, Goldblum D, et al. Cytoarchitecture of the retinal ganglion cells in the rat. Invest Ophthalmol Vis Sci. 2002;43:587-594.
46. Sagdullaev BT, McCall MA, Lukasiewicz PD. Presynaptic inhibition modulates spillover, creating distinct dynamic response ranges of sensory output. Neuron. 2006;50:923-935.
47. Tian N, Copenhagen DR. Visual deprivation alters development of synaptic function in inner retina after eye opening. Neuron. 2001;32:439-449.
48. Lyons JG, Siew K, O'Grady RL. Cellular interactions determining the production of collagenase by a rat mammary carcinoma cell line. Int J Cancer. 1989;43:119-125.
49. Bhattacharjee J, Nunes Cardozo B, Kamphuis W, Kamermans M, Vrensen GF. Pseudo-immunolabelling with the avidin-biotin-peroxidase complex (ABC) due to the presence of endogenous biotin in retinal Muller cells of goldfish and salamander. J Neurosci Methods. 1997;77:75-82.
50. Lam TT, Abler AS, Kwong JM, Tso MO. N-methyl-D-aspartate (NMDA)-induced apoptosis in rat retina. Invest Ophthalmol Vis Sci. 1999;40:2391-2397.
51. Krainc D, Bai G, Okamoto S, et al. Synergistic activation of the N-methyl-D-aspartate receptor subunit 1 promoter by myocyte enhancer factor 2C and Sp1. J Biol Chem. 1998;273:26218-26224.
52. Aihara M, Lindsey JD, Weinreb RN. Enhanced FGF-2 movement through human sclera after exposure to latanoprost. Invest Ophthalmol Vis Sci. 2001;42:2554-2559.
53. Relton JK, Rothwell NJ. Interleukin-1 receptor antagonist inhibits ischaemic and excitotoxic neuronal damage in the rat. Brain Res Bull. 1992;29:243-246.
54. Hagan P, Poole S, Bristow AF, Tilders F, Silverstein FS. Intracerebral NMDA injection stimulates production of interleukin-1 beta in perinatal rat brain. J Neurochem. 1996;67:2215-2218.
55. Hara H, Friedlander RM, Gagliardini V, et al. Inhibition of interleukin 1beta converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage. Proc Natl Acad Sci USA. 1997;94:2007-2012.
56. Kido N, Inatani M, Honjo M, et al. Dual effects of interleukin-1beta on N-methyl-d-aspartate-induced retinal neuronal death in rat eyes. Brain Res. 2001;910:153-162.
57. Kitaoka Y, Munemasa Y, Nakazawa T, Ueno S. NMDA-induced interleukin-1beta expression is mediated by nuclear factor-kappa B p65 in the retina. Brain Res. 2007;1142:247-255.
58. Kwong JM, Lam TT. N-methyl-D-aspartate (NMDA) induced apoptosis in adult rabbit retinas. Exp Eye Res. 2000;71:437-444.
59. Timmer JC, Salvesen GS. Caspase substrates. Cell Death Differ. 2007;14:66-72.
60. Escalona-Benz E, Jockovich ME, Murray TG, et al. Combretastatin A-4 prodrug in the treatment of a murine model of retinoblastoma. Invest Ophthalmol Vis Sci. 2005;46:8-11.
61. Economopoulou M, Bdeir K, Cines DB, et al. Inhibition of pathologic retinal neovascularization by alpha-defensins. Blood. 2005;106:3831-3838.
62. Cruysberg LP, Franklin AJ, Sanders J, et al. Effective transscleral delivery of two retinal anti-angiogenic molecules: carboxyamidotriazole (CAI) and 2-methoxyestradiol (2ME2). Retina. 2005;25:1022-1031.
63. Olsen TW, Edelhauser HF, Lim JI, Geroski DH. Human scleral permeability: effects of age, cryotherapy, transscleral diode laser, and surgical thinning. Invest Ophthalmol Vis Sci. 1995;36:1893-1903.
64. Kim TW, Lindsey JD, Aihara M, Anthony TL, Weinreb RN. Intraocular distribution of 70-kDa dextran after subconjunctival injection in mice. Invest Ophthalmol Vis Sci. 2002;43:1809-1816.
65. Barnett EM, Elangovan B, Bullok KE, Piwnica-Worms D. Selective cell uptake of modified Tat peptide-fluorophore conjugates in rat retina in ex vivo and in vivo models. Invest Ophthalmol Vis Sci. 2006;47:2589-2595.